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Recently, remarkable efforts have focused on research towards enhancing and delivering efficacious and
advanced therapeutic agents. Even though this involves significant challenges, innovative techniques
and materials have been explored to overcome these. The advantageous properties of mesoporous silica
nanoparticles (MSNs), such as unique morphologies and geometries, makes then favorable for use for
various drug delivery targeting purposes, particularly in cancer therapy. As we discuss here, MSNs have
been utilized over the past few decades to improve the efficiency of anticancer drugs by enhancing their
solubility to render them suitable for application, reducing adverse effects, and improving their
anticancer cytotoxic efficiency.Introduction
Over recent years, various different studies have focused on the
application of mesoporous silica-based platforms as effective
nanocarriers in chemotherapy [1]. Mesoporous silica has favorable
properties for use as a nanocarrier, such as large pore volume, large
surface area, and adjustable pore morphological structures [2,3].
The characteristics of inorganic silica (e.g., size, surface, and
topology) can be altered to generate distinct interactions with differ-
ent types of biological system. Thus, mesoporous silica, amorphous
silica, microporous crystalline titanosilicates, and zeolites have been
widely used in biomedical applications [4]. The desirable features of
mesoporous inorganic materials, more specifically MSNs, are easily
tailoredto incorporate and interact effectively with an arrayofpoorlyPlease cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
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https://doi.org/10.1016/j.drudis.2020.06.006 soluble drugs and biomolecules. thus, it is clear to see why there is a
growing interest inthis field[5,6]. Ordered MSNs are characterized by
particle size (50–200 nm), pore sizes of 2–6 nm, bulk pore volume of
0.6–1 cm3/g and a large surface area of 700–1000 m2/g. Moreover,
MSNs have the ability to bind to various kinds of functional groups of
active pharmaceutical ingredients (APIs) to allow targeted delivery to
the required site of action. These explicit characteristics render MSNs
as promising nanocarriers that have revolutionized different drug
delivery approaches [7], such as controlled [8], targeted [9,10], sus-
tained [11], and responsive systems [12–14]. The characteristics of
MSNs have been studied in depth with respect to their pharmacoki-
netic and immunological properties, which are major challenges to
overcometorealizetheirpotential intheclinic[15]. Inthisreview,we
discuss the different characteristics of MSNs and emphasize their
involvement in recent advances in different drug delivery systemses as drug delivery carriers for chemotherapeutic agents, Drug Discov Today (2020), https://
www.drugdiscoverytoday.com 1
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EEN(DDSs), with a specific focus on their potential biomedical use in
chemotherapy and cancer treatment.
MSNs as a targeting delivery system for anticancer
drugs
Recent research has resulted in the applications of several targeting
tools for use in drug discovery. Smart nanostructured vehicles havePlease cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
doi.org/10.1016/j.drudis.2020.06.006
TABLE 1
Applications of MSNs in cancer therapy
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2 www.drugdiscoverytoday.combeen utilized to improve the efficacy of anticancer drugs while
reducing their nonselective adverse effects on nontarget tissues
[16–19]. Different surface modification procedures have been used
to achieve targeted localized delivery of anticancer agents to
improve their efficiency in reducing tumor progression and their
adverse effects [19]. MSNs have been used to successfully deliver
different types of chemotherapeutic drug, including doxorubicines as drug delivery carriers for chemotherapeutic agents, Drug Discov Today (2020), https://
r
Pore size Notes Refs
7 nm In vitro assays showed huge cytotoxicity and
significant induction of apoptosis
[57]
s Not stated Improved cancer suppression activity because of
higher accumulation of SO in hepatic tumor cells
[58]
s Not stated Enhanced antitumor activity and premature
release stimulated under pH 7.4 and fast drug
release under cancerous acidic environment (pH
6.5 and 5.0).
[62]
4 nm Improved cell internalization ( 25%) observed in
simulated physiological medium
[63]
2.754 nm Bilipid layer improved loading of drugs by
enhancing their solubility, exhibited prolonged




3.36 nm pH-responsive targeting; in vitro drug release
profile exhibited controlled pH-responsive and
enhanced drug release rate; cytotoxic against
breast cancerous cells
[59]
Not stated Synergistic effect; chemotherapeutic effect of
DOX loaded in mesoporous shell; photothermal
effect of gold core; resulted in significant damage
to cancer cells
[29]
s Not stated Enhanced cytotoxicity and induction of selective
apoptosis resulting from co-delivery of cisplatin
and DOX simultaneously with BCL2 and MRP1
siRNAs. In vivo assays showed MSNs were inhaled
through lungs, avoiding their uptake by systemic
circulation
[64]
4.1 nm Synergetic effect of bortezomib and HMSNs
demonstrated improved tumor apoptosis
[65]
7.8 nm In vitro studies confirmed high loading drug
capacity (785.7 mg/g), excellent compatibility,
and good pH-triggered response
[66]
2.9 nm Guar gum capping used as effective in vivo
enzyme-responsive carrier
[67]
3.6 nm Tf-magnetic field resulted in high drug delivery
capacity with enhanced cytotoxicity and release





Not stated Tailoring particle size and functionalization of
MSNs achieved improved efficacy and targeting
against glioma cell lines
[70]
2.4 nm PAA acted as gatekeeper, reducing premature
release of drug and resulting in pH-responsive
release in tumor target site; ligand-selective
binding to cancer cells overexpressing glycans (e.
g., sialic acids)
[14]
Not stated A new approach to using MSNs in detection of
early-stage ovarian cancer using nanostructured
formulations
[13]
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(DOX) [20] and paclitaxel [21], which resulted in inhibitory effects
on tumors. Table 1 highlights the range of MSN applications in
cancer therapy.
Three distinct approaches have been developed when utilizing
MSNs: passive targeting, active (cell-selective) targeting, and con-
trolled stimulus-responsive release targeting [22]. Several studies
have shown the defective structure of blood vessels in tumors
tissues, which allows different vascular permeability in cancer
cells. Therefore, most solid tumors are characterized by a degree
of vascular permeability, which provides a suitable supply of
oxygen and nutrients that enable the fast growth of cancerous
tissues. This is known as the enhanced permeability and retention
(EPR) effect [23]. As a result of this effect, any macromolecules
(>40 kDa) can selectively escape from cancerous blood vessels and
accumulate in cancerous tissues [24]. By contrast, the EPR effect
does not occur in normal tissues. Thus, in solid tumor tissues, the
EPR effect can be a target for chemotherapeutic agents and is
increasingly emerging in drug delivery science as a promising
clinical treatment [23].
Passive targeting
To accomplish effective targeting delivery of NPs, it is crucial to
extend their circulation time through the mononuclear phagocyt-
ic system (MPS) and decrease their rate of renal clearance. There-
fore, it is essential for nanoparticles to be 10 nm diameter and 100–
200 nm size [25] to penetrate the tumor tissues via passive diffu-
sion and to avoid the MPS [26,27]. Meng et al. reported effective
passive targeting using polyethyleneimine-polyethylene glycol
(PEG)-functionalized MSNs with a particle size of 50 nm [28].
The results indicated an improvement in DOX delivery through
passive diffusion to cancerous cells. This system not only achieved
the EPR effect, but also improved DOX cellular uptake by tumor
cells by using a nanostructured particulate system. Therefore, it
preferably induced cellular apoptosis and tumor size reduction
alongside avoiding severe DOX cytotoxic effects [28]. Another
study demonstrated that mesoporous silica-coated gold nanorods
showed an efficient passive targeting effect [29]. This unique
nanodevice exerted two synergistic therapeutic effects; the che-
motherapeutic effect of DOX loaded in the mesoporous shell and
the photothermal effect of the gold core. This nanosystem
achieved exceptional results compared with pure DOX, including
targeting tumor tissues, inducing damage to Ehrlich ascites carci-
noma in vivo, causing significant cytotoxicity to a breast cancer cell
line (MCF-7), and decreasing cytotoxic effects on normal tissues
[29].
Active targeting
Active targeting can be used to improve the therapeutic efficiency
of a drug by overcoming the challenges associated with passive
targeting systems, such as the lack of the ability to control
entrapped API release and reduced tumor specificity. In active
targeting, specific ligands are conjugated to MSNs via surface
modification. Ligand-modified MSNs tend to recognize receptors
that are selectively expressed on the membrane of cancerous cells
via ligand–receptor interactions, therefore improving the antitu-
mor selectivity [26,27]. The ligands could be peptides [30], apta-
mers [31], antibodies [32], proteins [33], saccharides [34], and folic
acid [35]. Active targeting offers a pathway for selective localizedPlease cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
doi.org/10.1016/j.drudis.2020.06.006delivery of anticancer drugs to tumor cells, causing efficient cellu-
lar endocytosis [6]. Bioactive molecules, such as folic acid, have
been used extensively to deliver several anticancer therapeutics to
different kinds of tumor (i.e., those that overexpress folate recep-
tors on their surfaces) including lung, ovarian, breast, kidney,
endometrial, colon, and brain cancers [36]. A recent study devel-
oped a smart device compromising functionalized hyaluronic acid
(HA) MCM-41-type MSNs to achieve active targeting utilizing two
different molecular weights of HA (6.4 and 200 kDa). The study
demonstrated that optimizing different parameters, including the
method of loading and molecular weight of HA, resulted in the
enhanced stability and dispersity of MSNs in biological fluids. It
indicated that high-molecular-weight HA-functionalized MSNs
demonstrated high biocompatibility, low cytotoxicity, and favor-
able targeted binding to HA receptors (CD44) that are overex-
pressed in many cancerous cells. These results suggest that HA-
functionalized MSNs are a promising platform for cancer-targeting
therapy [10].
Responsive targeting systems
Stimuli-responsive systems are an advanced strategy that provides
on-demand release of therapeutic molecules in response to exter-
nal or internal stimuli [22]. The on-demand release of APIs inside
specific intracellular compartments can be only achieved as a
response to explicit endogenous or exogenous changes in the
microenvironment of the cells [37]. These changes can be triggered
by external stimuli (e.g., electricity, temperature, ultrasound,
light, and magnetism) and internal stimuli (e.g., enzymes, reactive
oxygen species, redox potential, pH, and ionic strength). Never-
theless, on-demand release (which is triggered by intracellular
stimuli) is a more suitable pathway for clinical applications [38].
Here, MSNs are utilized to protect cargo molecules from premature
release and only allow their release upon exposure to stimuli that
are selectively present in the tumor tissues [39], such as acidic pH
[13] and enzymes [20,40]. Many studies have used this responsive
release strategy to improve the treatment outcomes of chemother-
apy, including its safety and efficacy [6]. Three essential routes can
be utilized to achieve on-demand release: modifying the surface of
MSNs via a responsive polymer coating [41], attaching certain
ligands (gatekeeper) to their mesopores [42], or anchoring the
anticancer agent to MSNs via responsive cleavable linkers [43].
The flexibility of MSN synthesis techniques has enabled their
layer-by-layer construction to result in mate4rial of an accurate
thickness, which results in advantages including permeability
properties and elasticity [44,45]. The delivery of their cargo
depends on interactions between molecular charges. When the
pH is neutral, charges are electrostatically stable and the layers stay
locked, which maintains the cargo within the layers and avoids its
premature release. Once the pH shifts, the molecular charges react,
destroying the multilayered assemble to release the cargo for
targeted delivery [46].
Protein regulation and metabolism result in acidic cancerous
tissues, with a pH range of 4–6.5 [47]. The difference in pH between
normal and cancerous cells can be useful in targeting drug delivery
[39]. The flexible MSN structure allows different molecules to
attach to their surface for specific targeting [48]. Functionalized
MSNs can be modified chemically via degradation or charge
conversion as a response to pH changes. These drug carriers tendes as drug delivery carriers for chemotherapeutic agents, Drug Discov Today (2020), https://
www.drugdiscoverytoday.com 3
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EENto be stable in a neutral pH environment (pH 7.4) and degrade
upon exposure to an acidic pH environment (e.g., tumor tissues)
[47]. Thus, MSNs have been exploited using this approach to
increase cellular uptake and to reduce the adverse effects of che-
motherapy. For example, an effective nanocarrier was developed
using conjugated MSNs to target bone cancer by exploiting their
pH-responsive properties [14]. A novel device of DOX-loaded
MSNs was formed that was coated with a polymeric shell (poly-
acrylic acid; PAA) via acid degradable linkage. PAA acted as a
gatekeeper to reduce the premature release of DOX but to allow
its release in response to changes in pH in the tumor site. A
synergist active targeting effect was provided by grafting lectin
concanavalin A into MSNs. This targeting ligand selectivity binds
to glycan (e.g., sialic acids)-overexpressing cancer cells. In vitro
studies showed that this novel DOX-loaded MSNs increased the
anticancer efficacy of DOX up to eightfold compared with free
drug [14].
MSNs are not only used for cancer therapy, but are also being
explored as a promising diagnostic approach to assist clinicians in
detecting tumors at earlier stages of disease. A recent study dem-
onstrated wormhole-shaped mesoporous silica nanoparticles
(WMSNs) for the diagnosis and detection of ovarian cancer owing
to their ability to target tumor tissues. With a diameter of 27 nm,
these MSNs were produced by sol-gel process and were loaded with
imaging probes for diagnosis purpose. WMSNs were functional-
ized with chitosan and a V7 pHLIP peptide to achieve the pH-
responsive release of the imaging probes only inside the acidic
environment of ovarian tumors, preventing their off-target pre-
mature release. Intravenous injection of this complex in mice
allowed the early detection of primary-stage ovarian tumor. Thus,
the study highlighted how nanostructured formulations can be
explored to discover tumors using constantly evolving imaging
technology [13].
MSN applications in chemotherapy
Cancer is a significant cause of morbidity in humans. Although
chemotherapy is considered to be the most potent anticancer
treatment, it does not destroy cancer tissues specifically, but
instead also affects noncancerous tissues [49]. To overcome this
issue, researchers have developed cargo delivery systems to in-
crease the drug concentration in tumor tissues and to improve the
delivery of the drug molecules to the target area [6,15].
The most crucial aspect of chemotherapy is the use of different
chemical entities to induce cellular apoptosis. However, the sys-
temic administration of cytotoxic therapeutic agents results in
cellular death in both cancerous and healthy tissue [1]. Given the
deficiency of selectivity of chemotherapeutic agents, severe ad-
verse effects [e.g., hair loss, myelosuppression, cardiotoxicity,
immunosuppression, mucositis (gastrointestinal tract inflamma-
tion) and neurotoxicity] can be induced [50], resulting in de-
creased patient compliance. For example, the use of the
anticancer drugs paclitaxel and docetaxel (derived from natural
sources and used for the treatment of solid tumors [51]) has been
restricted because of their cardiotoxicity effects and poor aqueous
solubility [22,52]. As a result, there have been various attempts to
enhance the therapeutic profiles of these cytotoxic compounds
and increase their applicability. In addition to toxicity, conven-
tional chemotherapy also suffers from the poor solubility of hy-Please cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
doi.org/10.1016/j.drudis.2020.06.006
4 www.drugdiscoverytoday.comdrophobic drugs, fast systemic elimination, and multidrug
resistance (MDR) [49]. MDR is defined by the ability of drug-
resistant tumors to express resistance simultaneously against sev-
eral functional and structural unrelated anticancer compounds
[53]. Therefore, research has focused extensively on developing
nanostructured chemotherapeutics carriers that are capable of
achieving anticancer on-site delivery to address MDR [1,54], result-
ing in various biomedical applications [22]. Among different
inorganic nanomaterials, MSNs have attracted significant interest
as effective vehicles in anticancer drug delivery because of their
flexible in vivo and in vitro properties [42]. The discovery of silica-
based nanoparticles was an important milestone in cancer therapy
owing to their favorable characteristics, such as biocompatibility,
chemical and thermal stability, tunable pore size, high pore vol-
ume, and ease of surface area alteration [36]. In addition, most
antitumor drugs demonstrate poor water solubility, poor perme-
ability across biological membranes, and inadequate bioavailabili-
ty that restricts their administration by intravenous or oral routes.
Thus, MSNs have been used to improve their solubility and en-
hance their permeability [55], resulting in a better accumulation of
anticancer drugs at the tumor site, improving their efficiency
[12,16,46,55].
Moreover, the structures of MSNs can be modified via diverse
stimuli-responsive gatekeepers to enhance drug release. In addi-
tion, ordered MSNs are able to carry a high payload, thus ensuring
controlled delivery for chemotherapeutics to cancerous tissues.
Their nanosize enables the EPR effect and their surface-grafted
ligands allow active targeting of specific molecular structures on
the surface of the cancer cells [22].
MSNs in liver cancer
Despite significant advances in treatments, mortality resulting
from liver cancer remains high worldwide [56]. There has been
much interest in the use of nanocarriers as a DDS to improve the
treatment of hepatic cancer. For example, arsenic trioxide (ATO),
an antileukemia drug, has been approved by the FDA as a chemo-
therapeutic agent for solid tumors. Chi et al. encapsulated ATO
prodrugs into the pores of large-pore MSNs (LPMSNs) to treat
hepatocellular carcinoma (HCC). The authors reported real-time
monitoring using magnetic resonance imaging by inserting mag-
netic iron oxide NPs into the MSN pores [57]. Stimuli-responsive
targeting was achieved by modification of the silica surface using
folic acid ligand (M-LPMSN-NiAsOx-FA). In vitro assays demon-
strated improved cytotoxicity efficacy compared with free ATO
because of a significant induction of apoptosis in SC-7721 cells.
Furthermore, in vivo showed a controlled release delivery system
through the imaging ability of M-LPMSN-NiAsOx-FA. Thus, this
work highlights the versatility of MSN-based platforms [57].
Anotherreport indicated a potentialcandidate for HCCtreatment
and tumor apoptosis via a combined chemo/photothermal line
therapy based on a MSN platform. A novel design of sorafenib
(SO), an antitumor agent and first-line HCC therapy, was developed
in this study. SO-Au-MSNs were obtained with a gold (Au) nanoshell
for photothermal conversion. The authors reported improved can-
cer suppression activity as a result of the higher accumulation of SO
in hepatic tumor cells. In response to near-infrared radiation, the
synergistic chemo/photothermal effect resulted in a higher drug
absorption rate and enhanced cytotoxicity of SO [58].es as drug delivery carriers for chemotherapeutic agents, Drug Discov Today (2020), https://
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Thus, multifunctional designated MSNs have resulted in in-
creased tumor death with respect to HCC, reducing the adverse
effects of the API while achieving its controlled release.
MSNs in breast cancer
MSNs have been explored to enhance the solubility of therapeutic
agents for use against breast cancer [52]. Given the obstacles of
administrating antitumor agents (including solubility and stabili-
ty), new tools have emerged to overcome these difficulties. For
example, some researchers used lipid bilayer-coated MSNs to co-
deliver two anticancer drugs (paclitaxel and curcumin) intrave-
nously to breast tumors with the aim of enhancing their bioavail-
ability and reducing adverse effects. Both drugs exhibit low
aqueous solubility and permeability, which results in their poor
bioavailability and adverse effects, limiting their therapeutic use.
Loading these agents into lipid bilayer-coated MSNs improved
their solubility, achieving a sustained release and enhancing their
cytotoxicity against breast cancer. The excellent dispersibility and
high surface area of the lipid bilayer-coated MSNs also allowed the
intravenous injection of the hydrophobic anticancer drugs [21].
In addition, pH-responsive MSNs have been developed for the









Examples of mesoporous silica nanoparticles (MSNs) in chemotherapy. (a) Transmi
chitosan (CH)-folate (FA) (ii); selected area (electron) diffraction (SAED) image of MSN
Scanning electron microscopy (SEM) images (i,ii) and TEM images (iii,iv) of SBA-1associating with chemotherapeutic drugs. The synthesis of MSNs
was accomplished to attain the carboxylic functional group CH.
For this purpose, ATZ was loaded into the pores of the MSNs,
which were capped with a chitosan-folate conjugate (MSN-ATZ-
CH-FA) (Fig. 1a). The in vitro drug release study demonstrated a
controlled pH-responsive and improved drug release profile, while
being selectively more cytotoxic to breast cancer cell lines. The
study also highlighted the usefulness of MSN engineered-based
systems as effective in vivo pH-responsive carriers that can restrict
cancer metastasis [59].
Surface modification of MSNs resulted in significantly improved
cargo bioavailability and cytotoxicity of the encapsulated drugs
against breast cancer with a sustained release profile. Thus, MSN-
based DDSs are considered to be promising carriers for breast
tumor therapies.
MSNs in prostate cancer
Prostate cancer is one of the most frequent tumors affecting men.
The treatment of prostate cancer has improved over the past few
years, leading to an increase in survival rates. However, it remains a
serious cause of death in several regions [60]. Owing to the
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ssion electron microscopy (TEM) images of MSNs (i), MSN-anastrozole (ATZ)-
s (iii) [56]. (b) TEM of MSN (i) and doxorubicin (DOX)/MSN@CaCO3 (ii) [59]. (c)
5 [63].
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EENcules can be attached to their pores for targeted delivery. To this
end, different studies have applied conjugated antibody/NP sys-
tems to treat prostate cancer. Despite the evolution of DDSs, there
have been no published reports of the use of MSNs as targeted
therapy against prostate tumors. However, research has been
reported on the administration of particular antibodies by MSNs
[61].
For example, Liu et al. successfully synthesized a biocompatible
encapsulated core/shell designed NP to promote tumor apoptosis
in prostate cancer cells (LNCaP-AI). In this study, DOX/
MSNs@CaCO3 was covered with an outer layer of cancerous cell
membrane (CM) to enable the MSNs to enter and accumulate at
high levels within, the tumor site. The surface modification of
MSN@CACO3 was introduced as a detachable pH-sensitive stimu-
lus for controlling DOX release without affecting the morphology
of the NP (Fig. 1b). Premature release was stimulated under pH 7.4
and fast DOX release under cancerous acidic environment (pH 6.5
and 5.0), showing better anticancer activity compared with free
DOX [62].
Another innovative drug delivery system was developed by
Rivero-Buceta et al., who reported a stable conjugated ligand of
DOX with an antiprostate-specific membrane antigen (PSMA)
molecule (anti-FOLH1 monoclonal antibody, clone C803 N) in
MSNs against LNCaP-AI cells. These MSNs demonstrated better
cell internalization (25%) in a simulated physiological medi-
um. Moreover, the cytotoxicity of DOX increased twofold com-
pared with untargeted NPs and free DOX. By contrast,
nonbearing-PSMA and PC3 cell lines showed a lack of targeting
efficiency. Therefore, this study highlights the potential use of
MSNs against non-metastatic prostate cancer [63].
MSNs in lung cancer
Annually, almost 220 000 people are found to have lung cancer in
the USA. There are two different kinds of lung cancer; non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Significant progress has been made in this field using MSNs, which
can be administrated via the inhalation route to deliver drugs to
lungs to achieve local targeted action.
For example, the delivery of cisplatin and DOX simulta-
neously with BCL2 and MRP1 small interfering (si)RNAs to
lungs has been accomplished using MSNs. This co-delivery
system is administered via inhalation to target lung carcino-
ma. Additionally, a targeting peptide (LHRH) was attached to
the MSN surface using PEG as a linker. This unique combina-
tion inhibited both pump and nonpump-resistance mecha-
nisms, enhancing the cytotoxicity of the loaded anticancer
drugs and inducing selective apoptosis of NSCLC. In vivo
administration of MSNs through inhalation achieved a local
preferential targeting action in murine lungs and avoided their
escape to the systemic circulation. This was evidenced by
accumulation of 73% of MSNs in the lungs and their absence
or minor presence in other tissues (spleen, heart, kidney, and
liver). By contrast, intravenous administration of MSNs caused
serious accumulation of the NPs in liver (73%), with only 5%
being found in lungs [64].
Another study established a nanocarrier delivery system includ-
ing the encapsulation of bortezomib (a proteasome inhibitor) and
p35 into hollow MSNs (HMSNs) for the treatment of NSCLC. ThePlease cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
doi.org/10.1016/j.drudis.2020.06.006
6 www.drugdiscoverytoday.comstudy enhanced the efficacy of the encapsulated drug and
prompted p35 signal pathways. Given the synergetic effect of
bortezomib and HMSNs, tumor apoptosis was clearly achieved.
p35 exhibited slow release under normal physiological conditions
and very fast under acidic conditions (lysosomes and endosomes)
[65].
Thus, advances in DDSs based on MSN nanocarriers have
resulted in local targeted delivery via inhalation, improved accu-
mulation of anticancer drugs in the target area, and successful
gene delivery to tumor sites, achieving tumor suppression.
MSNs in colon cancer
The application of capped MSNs has achieved successful treatment
of colon cancer using the oral route because of their ability to
enhance the solubility of hydrophobic anticancer drugs targeting
colon carcinomas, preventing premature drug release [66]. For ex-
ample, a pH-triggered nanodevice was developed based on PAA-
functionalized SBA-15 type MSNs (Fig. 1c). PAA acted as a gatekeeper
to retain DOX molecules within SBA-15 mesopores during their
transportation to the target site. Under gastric conditions (pH 2.0),
DOX was protected from premature leakage whereas, under colonic
conditions (pH 7.6), DOX demonstrated immediate release. In vitro
studies showed a high loading drug capacity (785.7 mg/g), excel-
lent compatibility, and a good pH-triggered response. Furthermore,
thisstudyindicatedtheimproved solubilityofDOXmolecules inthe
colonic environment [66].
Kumar et al. investigated a colon cancer treatment using MCM-
41-type MSNs to increase the effectiveness of 5-flurouracil (5-FU)
using an enzyme-responsive system. They functionalized MSNs
with a natural polymer (guar gum) to retain the drug inside
mesoporous channels under physiological conditions. 5-FU re-
lease was activated through the degradation of the guar gum
cap in response to colonic enzymatic activity. The release of the
anticancer agent was around zero when the enzymes were absent
in different gastrointestinal tract conditions. thus, the study high-
lights another significant form of MSN engineered-based systems
using guar gum capping as an effective in vivo enzyme-responsive
carrier [67].
MSNs in brain cancer
Although there has been great progress in the detection of differ-
ent cancers, many challenges remain associated with brain can-
cers. A major form of brain cancer is a high-grade malignant
glioma, glioblastoma multiforme (GBM), which is defined by
the successive growth and immediate damage of brain parenchy-
ma. Given its strong resistance to chemotherapy, fast cell damage,
intense frequency of relapse, and poor survival rates, GBM is
classified as a life-threatening tumor [68]. Step-by-step exploration
of mesoporous silica materials has enabled the development of an
innovative drug delivery platform for use against GBM [36].
A study reported improved anticancer drug delivery to GBM by
using protein-grafted MSNs. Transferrin (Tf), a biological blood
glycoprotein, was added to the external surface of the MSNs with
conjugated magnetic silica poly(d,l-lactic-co-glycolic acid) NPs
(MNP-MSN-PLGA-Tf NPs). In these NPs, Tf is considered as both
the gatekeeper and the targeting agent to achieve the better
therapeutic efficiency of DOX The abundant presence of the Tf-
magnetic field resulted in DOX being delivered with higher cyto-es as drug delivery carriers for chemotherapeutic agents, Drug Discov Today (2020), https://
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toxicity and enhanced release rate compared with free DOX. Thus,
Tf-modified MSNs are a potential carrier system that can suppress
tumor growth, resulting in a selective cytotoxic effect against GBM
and reducing systemic adverse effects [69].
Mo et al. tailored the size of MSNs to successfully cross the
blood–brain barrier to target GBM. The authors fabricated differ-
ent-sized MSNs (20,40, and 80 nm) with capped arginylglycylas-
partic acid peptide cRGD-conjugated DOX. This allowed the MSNs
to selectively attach to U87 cells with a large anb3 integrin and
improved cellular uptake using a particle size of 40 nm. Thus,
amending the particle size and functionalization of MSNs could be
an effective approach to target GBM via a sequentially enhanced
cancer-targeting effect [70].
Concluding remarks and perspectives
Despite significant research on MSNs and their potential as a
cancer therapeutic, there remains a lack of MSNs in clinic practice
owing to the their inability to be successfully delivered to and
accepted by living organisms hence hindering the process to
clinical trials [71]. Nevertheless, they have shown great progress
in their use as imaging systems and theranostics, specifically in
aiding the diagnosis of ovarian cancers [13].
Various technologies are involved in the engineering of these
carriers. Conventional methods, such as solvent impregnation, are
common fabrication methods that have successfully yielded MSNs
[5,32]. More recent emerging engineering technologies, such as
electrohydrodynamic atomization (EHDA), have started to be
exploited to develop MSNs in a simple one-step, cost-,effectivePlease cite this article in press as: Alyassin, Y. et al. Application of mesoporous silica nanoparticl
doi.org/10.1016/j.drudis.2020.06.006method [72,73]. By utilizing ever-evolving technologies,
these beneficial carriers can be continuously fabricated in a
cost-effective, easily adaptable, and modified way that can be
altered to fit specific requirements or criteria, rendering them
attractive for personalized drug delivery and therapy.
This review focused on recent applications of MSNs from a
chemotherapy prospective. In addition, it highlighted the relevant
characteristics of MSNs, such as adjustable pore size, high surface
area, bioactivity, and release properties, and the different types of
technique used, to deliver safe and compatible anticancer APIs.
Despite the challenges associated with delivering a drug, significant
progress has been made in the biomedical field, particularly with
MSNs.Moreover, numerous methodscanbeused toaidMSN-surface
modifications to enhance the responsive releaseof drugsand control
drug delivery. MSNs can be also used in optical imaging to in
diagnose tumors at early stages of disease. Thus, effective MSN-based
platforms could in the future overcome the disadvantages associated
with current stand-of-care chemotherapy.
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